(Q36277926)

13 August 2017

1 reference

title

N-acetylcysteine for prevention of radiographic contrast material-induced nephropathy: is the intravenous route best? (English)

1 reference

13 August 2017

1 reference

6

John G Webb

1 reference

13 August 2017

Stephen J Shalansky

1

1 reference

13 August 2017

Thanh Vu

2

1 reference

13 August 2017

Gordon E Pate

3

1 reference

13 August 2017

Adeera Levin

4

1 reference

13 August 2017

Karin H Humphries

5

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

25

1 reference

13 August 2017

issue

8

1 reference

13 August 2017

page(s)

1095-1103

1 reference

Renal implications of percutaneous coronary intervention

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

Role of N-acetylcysteine in the prevention of radiocontrast-induced nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: a randomized controlled trial of intravenous N-acetylcysteine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

Contrast nephropathy : an evidence-based approach to prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

Contrast nephropathy after coronary angiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

N-acetylcysteine in the prevention of radiocontrast-induced nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

Nitric oxide and S-nitrosothiols in human blood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

N-Acetylcysteine potentiates inhibition of platelet aggregation by nitroglycerin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

N-acetylcysteine ameliorates renal microcirculation: studies in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

The effect of N-acetylcysteine on renal function, nitric oxide, and oxidative stress after angiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

Pharmacokinetics of N-acetylcysteine in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

Effect of N-acetyl cysteine on the concentrations of thiols in plasma, bronchoalveolar lavage fluid, and lung tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

Nephrotoxic effects in high-risk patients undergoing angiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

Contrast media-induced nephrotoxicity: identification of patients at risk and algorithms for prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

Acetylcysteine for prevention of contrast nephropathy: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

Systematic review of the impact of N-acetylcysteine on contrast nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

A randomized comparison of the nephrotoxicity of iopamidol and diatrizoate in high risk patients undergoing cardiac angiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

Acetylcysteine and contrast agent-associated nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

Prevention of contrast nephropathy after cardiac catheterisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

Effect of N-acetylcysteine on serum creatinine level

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

Acetylcysteine, coronary procedure and prevention of contrast-induced worsening of renal function: which benefit for which patient?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

Role of N-acetylcysteine in prevention of contrast-induced nephropathy after cardiovascular procedures: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

Improved outcome with novel device for low-pressure PTCA in de novo and in-stent lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.8.1095

10.1592/PHCO.2005.25.8.1095

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference